The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P‐selectin glycoprotein ligand‐1 (PSGL‐1) gene polymorphism in multiple myeloma

Abstract

Somatic mutations and polymorphisms may play a role in multiple myeloma (MM) susceptibility and survival. One of the immune checkpoint inhibitors is P‐selectin glycoprotein ligand‐1 (PSGL‐1); the majority of tumor‐infiltrating leukocytes express PSGL‐1, causing T cell and immune inhibition via PSGL‐1 mediator molecules. We aimed to investigate the effect of variable number of tandem repeat (VNTR) polymorphism in the second exon of the PSGL‐1 gene on MM susceptibility, response to treatment and survival in our patient group. A total of 238 patients diagnosed with MM between January 2010 and January 2021 and 162 healthy individuals as a control group were included in this cross‐sectional study. The genotypes of the VNTR polymorphism in the second exon of the PSGL‐1 gene were statistically compared between patients and healthy controls; the statistically significant effects of the genotypes on response to first‐line treatment and survival were examined. The AC genotype was significantly higher in healthy controls compared to patients diagnosed with MM (p < 0.001). The median PFS in patients with AA/AB/AC was 56 months, while it was 100 months in patients with BB/CC. The hazard ratio of 1.34 for PFS was found to be clinically significant and having the BB/CC genotype could provide a longer PFS compared to others, but it was not statistically significant due to the sample size. Our study results will shed light on new study plans in terms of immune checkpoint target therapies among conventional treatment preferences in MM.